Veritas Asset Management LLP Bei Gene, Ltd. Transaction History

Veritas Asset Management LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$189.18 - $286.44 $756,720 - $1.15 Million	-4,000 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$121.84 - $173.19 $487,360 - $692,760	4,000 New	4,000 $492,000
Q4 2019 Feb 05, 2020	SELL	$115.78 - $208.34 $694,680 - $1.25 Million	-6,000 Closed	0 $0
Q1 2019 May 02, 2019	BUY	$122.82 - $151.83 $736,920 - $910,980	6,000 New	6,000 $792,000
Q3 2018 Oct 26, 2018	SELL	$152.62 - $189.66 $3.36 Million - $4.17 Million	-22,000 Closed	0 $0
Q2 2018 Aug 01, 2018	BUY	$152.5 - $216.77 $3.36 Million - $4.77 Million	22,000 New	22,000 $3.38 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Veritas Asset Management LLP, based on Form 13F filings with the SEC.

Stay updated on Veritas Asset Management LLP with notifications on news.